Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Anti-CD16-anti-CD30 monoclonal antibody

Drug Profile

Anti-CD16-anti-CD30 monoclonal antibody

Alternative Names: Anti-CD16-anti-CD30 bispecific monoclonal antibody; Anti-CD30-anti-CD16 bispecific monoclonal antibody; Anti-CD30-anti-CD16 monoclonal antibody

Latest Information Update: 22 Mar 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Biotest
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action Antibody-dependent cell cytotoxicity; Lymphocyte stimulants; Natural killer cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hodgkin's disease

Most Recent Events

  • 22 Mar 2007 Discontinued - Phase-II for Hodgkin's disease in Germany (IV-infusion)
  • 14 Sep 2000 A phase II study has been added to the Cancer therapeutic trials and pharmacodynamics sections
  • 28 May 1997 A study has been added to the therapeutic trials and adverse events sections
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top